The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting…